Hepatitis C

Effectiveness of Ledipasvir/Sofosbuvir for Acute HCV Infection in HIV

Effectiveness of Ledipasvir/Sofosbuvir for Acute HCV Infection in HIV

By

Study evaluated the optimal duration of ledipasvir/sofosbuvir for the treatment of acute hepatitis C virus (HCV) infection in HIV.

Preventing HCV Transmission: Utility of Needle/Syringe Programs

Preventing HCV Transmission: Utility of Needle/Syringe Programs

By

Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject drugs in Europe and North America, respectively.

Reduced Risk of Hepatic Steatosis in HIV/HCV Coinfection With Cannabis Use

Reduced Risk of Hepatic Steatosis in HIV/HCV Coinfection With Cannabis Use

By

Daily cannabis use remained significantly associated with lower odds of steatosis even after adjustment for BMI, which is known to be inversely correlated with cannabis use.

Increasing HCV Screening Using Electronic Health Record Prompts

Increasing HCV Screening Using Electronic Health Record Prompts

By

The rates of anti-HCV orders and tests were collected from 4 medical specialties within a 30 mile radius of University of Michigan, Ann Arbor campus.

A New Treatment Option for Patients With HCV and Severe Renal Impairment

A New Treatment Option for Patients With HCV and Severe Renal Impairment

By

Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, exhibit potent antiviral activity across all six major HCV genotypes.

Hepatitis C Transmission With Increased Risk Donor Organs Examined

Hepatitis C Transmission With Increased Risk Donor Organs Examined

By

Given the ongoing shortage of liver grafts, transplantation from HCV increased-risk donors to anti-HCV-negative recipients could potentially expand the donor pool.

Using VA Models of Care for Reducing HCV Burden

Using VA Models of Care for Reducing HCV Burden

The US VA has developed models of care that can be used to reduce the overall burden of HCV infection.

Short-Duration Treatment Regimens for Chronic HCV: Latest Insights

Short-Duration Treatment Regimens for Chronic HCV: Latest Insights

By

The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved treatment adherence, and a reduced rate of side effects.

HIV/HCV Co-Infections: Barriers to Effective Treatment

HIV/HCV Co-Infections: Barriers to Effective Treatment

By

Only a small percentage of people with HIV/HCV co-infection receive treatment for hepatitis C.

Efficacy of Ravidasvir Plus Sofosbuvir for Chronic Hepatitis C Genotype 4

Efficacy of Ravidasvir Plus Sofosbuvir for Chronic Hepatitis C Genotype 4

By

Researchers believe new once-daily dose of ravidasvir plus sofosbuvir is effective in treatment HCV genotype-4 and may be cost effective.

Direct-Acting Antivirals: The Gold Standard for HCV Recurrence Following Transplantation?

Direct-Acting Antivirals: The Gold Standard for HCV Recurrence Following Transplantation?

By

The majority of patients treated with second-generation direct-acting antiviral agents achieved sustained virologic response in 12 weeks.

Hepatitis C Treatment With Direct-Acting Antivirals Confers Survival Benefit

Hepatitis C Treatment With Direct-Acting Antivirals Confers Survival Benefit

By

Primary endpoints are to achieve sustained virologic response, improve survival rates, and lower complications of HCV.

Development Program for Hepatitis C Treatments Discontinued

Development Program for Hepatitis C Treatments Discontinued

By

Merck announced that the development programs for two hepatitis C virus infection treatments have been discontinued.

New HCV Guidelines Focus on Patient Population Treatments

New HCV Guidelines Focus on Patient Population Treatments

By

The American Association of the Study for Liver Diseases and the Infectious Diseases Society of America have added additional guidelines for the treatment of hepatitis C virus.

Law Implementation of HCV Testing Increases Screening Rates

Law Implementation of HCV Testing Increases Screening Rates

Mandating health care providers to offer hepatitis C virus screening can increase screening rates and linkage to care.

Treating Hepatocellular Carcinoma: A Fight Against the Odds

Treating Hepatocellular Carcinoma: A Fight Against the Odds

By

Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are diagnosed at an advanced stage of the disease.

Once-Daily Treatment Regime for Hepatitis C With Compensated Cirrhosis

Once-Daily Treatment Regime for Hepatitis C With Compensated Cirrhosis

By

Researchers assessed safety and tolerability throughout the 12 week study period and 24 weeks after completion of last dose of glecaprevir coformulated with pibrentasvir.

Effective HCV Treatment Decreases Chronic Kidney Disease Incidence

Effective HCV Treatment Decreases Chronic Kidney Disease Incidence

By

Minimally effective treatment of hepatitis C virus can prevent th edevelopment of chronic kidney disease.

Does Sustained Virologic Response Improve Glycemic Control in HCV?

Does Sustained Virologic Response Improve Glycemic Control in HCV?

By

Researchers compared HbA1c changes and use of antidiabetic medication in HCV with diabetes.

HCC Risk After HCV Direct-Acting Antiviral Treatment

HCC Risk After HCV Direct-Acting Antiviral Treatment

By

The occurrence or recurrence risk for hepatocellular carcinoma is unclear after direct-acting antiviral agents and interferon based therapy.

Update on Pediatric HCV: Screening, Treatment, and Other Considerations

Update on Pediatric HCV: Screening, Treatment, and Other Considerations

By

Experts discuss screening, treatment, and other considerations in pediatric HCV.

DAAs Effective for HCV in Patients With Thalassemia

DAAs Effective for HCV in Patients With Thalassemia

By

Researchers compared the safety and efficacy of sofosbuvir plus ledipasvir vs pegylated interferon and ribavirin for 12 weeks in patients with thalassemia major and hepatitis C virus genotype 1 or 4.

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

By

HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.

CDC: More Interventions Needed to Aid HCV Elimination Program in Country of Georgia

CDC: More Interventions Needed to Aid HCV Elimination Program in Country of Georgia

More interventions are needed to meet the target of hepatitis C virus elimination in the country of Georgia, defined as a 90% reduction in prevalence by 2020.

 HCV Treatment Administered by Non-Specialists Safe, Effective

HCV Treatment Administered by Non-Specialists Safe, Effective

Non-specialists, including primary care providers and nurse practitioners, safely and effectively administer direct-acting antiviral therapy for hepatitis C virus to patients seen in FQHCs.

FDA Expands Epclusa® Indication for HCV/HIV Co-infection

FDA Expands Epclusa® Indication for HCV/HIV Co-infection

By

The FDA has approved an expanded indication for Epclusa to include the use of this once-daily single tablet regimen in patients co-infected with chronic hepatitis C virus and HIV.

Hepatitis C Virus Infection and Cardiovascular Disease Risk

Hepatitis C Virus Infection and Cardiovascular Disease Risk

By

Epidemiological data demonstrate a link between HCV infection and cardiovascular disease, whereas treatment studies suggest viral eradication may lower the risk for cardiovascular morbidity and mortality.

Steatosis: An Independent Risk Factor for Fibrosis in Chronic HCV

Steatosis: An Independent Risk Factor for Fibrosis in Chronic HCV

By

Steatosis, hypertension, older age, obesity, and HIV are risk factors for liver fibrosis in African-Americans with chronic hepatitis C.

Improving Hepatitis C Screening With EHR-Based Prompts

Improving Hepatitis C Screening With EHR-Based Prompts

Using an electronic health record-based can improve HCV screening rates among baby boomers.

FDA Approves Pan-Genotypic Treatment for HCV

FDA Approves Pan-Genotypic Treatment for HCV

By

FDA has approved Mavyret (glecaprevir and pibrentasvir) for the treatment of adults with chronic hepatitis C virus.

Sign Up for Free e-newsletters